Andrew Brenner, MD


Future Perspectives in HER2+ mBC

The panel closes their discussion by musing on the future of HER2 mBC treatments.

Binod Dhakal, MD, MS


Key Takeaways from Health Care Systems on the Role of Bispecifics in MM

The panel closes their discussion by highlighting crucial takeaways about the use of bispecific antibodies in the treatment of multiple myeloma.

Daniel V. T. Catenacci, MD


Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.

Laura Sanza, PhD, MPAS, PA-C


Renal Cell Carcinoma: Practical Advice for Patients, Caregivers, and Physicians

Practical advice on the management of renal cell carcinoma provided for healthcare professionals, patients, and caregivers alike.

Ankita Aggarwal, MD


Erdheim-Chester Disease: A Case Report of BRAF V600E–Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature Review

Investigators report a case of a man, aged 55 years, with an extensive and prolonged course of an unexplained multi-systemic disease, and also review common clinical manifestations, mutations, diagnoses, and targeted therapies for Erdheim-Chester disease.

Chasse Bailey-Dorton, MD, MSPH


Integrative Oncology in Young Women With Breast Cancer

Yancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.

Armin Ghobadi, MD


Armin Ghobadi, MD, on Recent Advancements in the Treatment of Patients with DLBCL

An expert in the treatment of diffuse large B-cell lymphoma explained some of the exciting advances in treatment and hypothesized what comes next after the 2020 ASH Annual Meeting & Exposition.

Rohit Gupta, MD


Unusual Initial Presentation of Hepatocellular Carcinoma as a Clavicular Head Mass

Rohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.

Daniel M. Geynisman, MD


Daniel M. Geynisman, MD, on Optimal Therapy Selection in RCC

At 2022 ASCO GU, Daniel M. Geynisman, MD, spoke with CancerNetwork® about his strategy for treating renal cell carcinoma across lines of therapy.

Satya Das, MD, MSCI


Satya Das, MD, MSCI, on Research Presented at the 2021 ASCO Gastrointestinal Cancer Symposium

The expert in hematology/oncology discussed what research he is most looking forward to seeing the results of at the meeting.

Lorena Nascimento Manrique Molina, BS


Psycho-Oncology and the Relevance of a Biopsychosocial Screening Program

Routine biopsychosocial screening of a patient with metastatic renal cell cancer at the Centro de Câncer de Brasília improved symptom management and shrunk costs for both the patient and her caregivers.

Michael J. Demeure, MD, MBA


Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1

ABSTRACT Advances in immuno-oncology over the last several years have led to FDA approvals of novel agents. As our understanding of immune response and its checkpoints has evolved, further advances have been made in treatment for several cancer types. To predict a response to immunotherapy, the initial biomarkers used were expression of the PD-1 receptor and PD-L1, as assessed by immunohistochemistry. More recently, predictive biomarkers have included microsatellite instability, DNA mismatch repair, and tumor mutational burden. Although these markers may be clinically relevant in predicting an immunotherapy response, cancer immunotherapy fails some patients. Improved understanding of the human immune system is necessary, as is a careful evaluation of the methods used to predict and assess response to Immuno-oncology treatments. With the application of therapeutic immune-modulating agents, more comprehensive assays, and associated bioinformatics tools to accurately assess the tumor microenvironment, we may better predict responses to immuno-oncology agents and the ever-increasing complexity of their clinical use.

Dan Vogl, MD


Treatment Response and Duration of Therapy in Transplant-Ineligible NDMM

Closing out their module on transplant-ineligible NDMM management, expert panelists consider best practices regarding duration of therapy and adjustments to drug regimens.

Andy Polhamus


Triplet Induction Chemotherapy Improves FFS in Nasopharyngeal Carcinoma Vs Doublet Regimen

Patients with stage IVA to IVB nasopharyngeal carcinoma experienced an improvement in failure-free survival following treatment with paclitaxel, cisplatin, and capecitabine for 2 cycles vs 2 cycles of cisplatin and fluorouracil.

Yi-Bin Chen, MD


Future Directions in Graft vs Host Disease Management

Closing out their panel on GVHD management, expert hematologist/oncologists share their hope for future evolution in the treatment landscape.

Ken Shain, MD, PhD


Multiple Myeloma: Unmet Needs and Future Perspectives

Closing out their discussion on the management of multiple myeloma, experts from the Moffit Cancer Center highlight key unmet needs and future directions in care.

Sailaja Darisipudi


Elacestrant Bests Standard of Care in PFS in ER Positive/HER2-Negative Metastatic Breast Cancer

Patients with ER-positive/HER2-negative metastatic breast cancer had improved progression-free survival when treated with elacestrant compared with standard of endocrine therapy.

Christian Buske, MD


Christian Buske, MD, on the Influence of CAR T-Cells Being Presented at ASH

The lymphoma expert spoke about the research being presented at the 2020 ASH Annual Meeting and what he believes has the potential to be most influential for treating this patient population.

Duke Herrell


Medical World News® Inside the Practice: CancerNetwork® and Duke Herrell on a Novel Suturing Technique for Transurethral Anastomosis

CancerNetwork® shares its latest investigation into novel practices for rendering surgical management of prostate cancer from experts at Vanderbilt Institute for Surgery and Engineering.

Christina Wu, MB, BCh, MD


Patient Scenario: A 66-Year-Old Male With BRAF-Mutant mCRC

Daniel Walden, MD, presents the scenario of a 66-year-old man diagnosed with BRAF V600E-mutant metastatic colorectal cancer to the expert panel for discussion.

Ana C. Garrido-Castro, MD


Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer

ABSTRACT The 21-gene Recurrence Score (RS) assay has been validated as both a prognostic and predictive tool in node-negative (pN0), estrogen receptor–positive (ER+), HER2-negative (HER2–) breast cancer. A large body of evidence supports the clinical utility of the RS in the node positive (pN+) population as well. Retrospective analyses of archived tissue from multiple clinical trials have found the RS to be prognostic in both endocrine therapy (ET)-treated and chemotherapy-treated patients with pN+ disease. Distribution of RS results in pN+ patients have also been consistent with those of pN0 populations. Data from the SWOG 8814 trial and large population-based registries further support the prognostic and potential predictive value of the RS. Specifically, patients with 1 to 3 positive nodes and RS less than 18 derived negligible benefit from adjuvant chemotherapy in these studies. In the prospective West German Study Group PlanB and ADAPT trials, pN+ patients with RS less than 11 and RS ≤25, respectively, who were treated with ET alone experienced excellent outcomes. Finally, 5-year results of the RxPONDER clinical trial randomizing patients with 1 to 3 positive nodes and RS ≤25 to ET alone vs ET plus chemotherapy confirmed an absence of chemotherapy benefit in postmenopausal patients. Clinical practice guidelines support use of the RS in the pN+, ER+/HER2– population, and many institutions have adopted the RS to guide clinical decision-making, resulting in a net reduction of adjuvant chemotherapy use. This review highlights the existing data supporting the prognostic and predictive ability of the RS in pN+ disease, current practice patterns related to RS use in this population, and emerging applications.

Rachael Galvin, DO, MPH


Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma

Molecular profiling is being explored in pancreatic adenocarcinoma as a tool to assist with early detection, prognosis, and patient selection in targeted therapy clinical trials.

Katie Kosko


Polygenic Score May Offer Personalized Treatment Options for Pediatric AML

Investigators used a patient-specific score to predict treatment outcomes in pediatric patients with acute myeloid leukemia, allowing them to identify who may benefit from higher-dose chemotherapy.

Tatev Arakelyan, MPH


Opsoclonus-Myoclonus–Associated Neuroblastoma With Bone Marrow Metastases: What Would Be the Best Treatment Option?

In this clinical quandary, investigators determine how to best treat patients with opsoclonus-myoclonus–associated neuroblastoma with bone marrow metastases.